New application of epiberberine

The invention discloses novel application of epiberberine and an experimental method for inhibiting osteoclast differentiation induced by breast cancer cells. It is proved for the first time that epiberberine cannot inhibit proliferation of osteoclast precursor cells at a high concentration (25 [mu] M), and the epiberberine has high biological safety. In addition, epiberberine has a remarkable inhibition effect on osteoclast formation induced by breast cancer and osteolysis induced by metastatic breast cancer. 本发明公开了表小檗碱的新用途以及抑制乳腺癌细胞诱导破骨细胞分化的实验方法。本发明首次证明表小檗碱在较高浓度时(25μM)不会抑制破骨细胞前体细胞的增殖，其具有较高的生物安全性。另外，表小檗碱对乳腺癌诱导破骨细胞形成、以及转移性乳腺癌诱导的骨溶解具有显著的抑制作用。